IFP Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-150
Closed -$9K 3457
2022
Q4
$9K Sell
150
-167
-53% -$9.4K ﹤0.01% 3432
2022
Q3
$18K Buy
317
+127
+67% +$6.77K ﹤0.01% 3167
2022
Q2
$11K Hold
190
﹤0.01% 3300
2022
Q1
$11K Buy
+190
New +$11.7K ﹤0.01% 3300
2020
Q1
Sell
-120
Closed -$8K 2770
2019
Q4
$8K Hold
120
﹤0.01% 2002
2019
Q3
$5K Buy
+120
New +$5.69K ﹤0.01% 2319
2019
Q1
Sell
-175
Closed -$7K 2458
2018
Q4
$7K Hold
175
﹤0.01% 2661
2018
Q3
$12K Hold
175
﹤0.01% 2729
2018
Q2
$10K Sell
175
-200
-53% -$10.9K ﹤0.01% 2878
2018
Q1
$21K Hold
375
﹤0.01% 2344
2017
Q4
$21K Buy
375
+100
+36% +$5.64K ﹤0.01% 2378
2017
Q3
$17K Sell
275
-725
-73% -$41.2K ﹤0.01% 2695
2017
Q2
$53K Buy
+1,000
New +$48.8K ﹤0.01% 1920

Other funds holding BIB

IFP Advisors's BIB Position: Q1 2023 in Review

IFP Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2023, closing a stake of 150 shares — an estimated $9K sold.

IFP Advisors first reported a position in BIB in Q2 2017 and held it in 13 quarters. The position peaked at $53K in Q2 2017. 24 funds tracked by Wall St. Rank hold BIB as of Q1 2023.

  • IFP Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2023 after selling out during the quarter.
  • IFP Advisors sold 150 ProShares Ultra NASDAQ Biotechnology shares in Q1 2023, an estimated $9K.
  • IFP Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2017 and held it in 13 quarters.
  • IFP Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $53K in Q2 2017.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.